Extended-release tacrolimus for pulmonary arterial hypertension
Part of Lungs & breathing clinical trials.
This study tests an extended-release form of tacrolimus, a medication that may help improve exercise ability in people with pulmonary arterial hypertension (PAH). It is for patients who still have symptoms despite current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pulmonary arterial hypertension (PAH), which is a type of high blood pressure in the lungs.
- Your symptoms are in functional class II to IV, meaning you have some limitations in daily activities.
- You have been on stable PAH treatments for at least 3 months.
- You can walk between 75 and 450 meters in a 6-minute walk test.
- You do not have certain other types of lung or heart conditions, and your kidney and liver function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called IKT-001 for people with pulmonary arterial hypertension (PAH). It aims to see if IKT-001 helps improve exercise ability and other symptoms when added to current PAH therapies.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.
This study tests an investigational drug called IKT-001 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It is open-label, meaning everyone knows they are getting the drug, and it is for people who have already been in a previous study of IKT-001.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.